iA Global Asset Management Inc. Has $10.67 Million Holdings in Abbott Laboratories (NYSE:ABT)

iA Global Asset Management Inc. raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 15.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,343 shares of the healthcare product maker's stock after acquiring an additional 12,768 shares during the quarter. iA Global Asset Management Inc.'s holdings in Abbott Laboratories were worth $10,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. State Street Corp boosted its holdings in Abbott Laboratories by 3.1% in the third quarter. State Street Corp now owns 76,720,429 shares of the healthcare product maker's stock valued at $8,746,896,000 after acquiring an additional 2,323,807 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Abbott Laboratories by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 34,903,198 shares of the healthcare product maker's stock valued at $3,963,974,000 after purchasing an additional 488,764 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Abbott Laboratories by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 25,810,977 shares of the healthcare product maker's stock worth $2,942,709,000 after buying an additional 280,441 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Abbott Laboratories by 25.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 13,319,347 shares of the healthcare product maker's stock valued at $1,518,539,000 after buying an additional 2,711,586 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Abbott Laboratories by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 12,940,321 shares of the healthcare product maker's stock valued at $1,463,680,000 after acquiring an additional 330,844 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Abbott Laboratories Stock Up 0.8 %

NYSE ABT traded up $0.97 during trading hours on Monday, hitting $127.31. 5,283,007 shares of the company traded hands, compared to its average volume of 5,481,777. The stock has a market capitalization of $220.79 billion, a price-to-earnings ratio of 16.64, a P/E/G ratio of 2.52 and a beta of 0.70. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The business's 50-day moving average is $128.79 and its 200-day moving average is $120.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion during the quarter, compared to analysts' expectations of $11.03 billion. During the same period last year, the business earned $1.19 earnings per share. The firm's revenue was up 7.2% on a year-over-year basis. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.85%. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.85%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the sale, the executive vice president now owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 116,449 shares of company stock worth $15,463,316. Company insiders own 1.10% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. UBS Group increased their price target on Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. The Goldman Sachs Group raised their target price on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Evercore ISI upped their price target on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. Bank of America lifted their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, StockNews.com lowered shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.94.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.